LECT2 Recombinant Rabbit mAb (SDT-2160-23)

Leukocyte cell-derived chemotaxin-2 (LECT2) is a 16-kDa secreted hepatic protein belonging to the M23 peptidase family that was first identified as a neutrophil chemoattractant but is now recognized as a multifunctional regulator of immunity, metabolism and tissue remodeling: produced chiefly by hepatocytes and released into the circulation, LECT2 modulates natural killer T-cell homeostasis in the liver, promotes chondrocyte and osteoblast proliferation, orchestrates inflammatory responses by inducing adhesion molecules and pro-inflammatory cytokines in endothelial cells, serves as a hepatokine linking obesity and fatty-liver–associated insulin resistance, exerts antiviral effects via the MET proto-oncogene, and when misfolded forms amyloid fibrils that cause LECT2 amyloidosis primarily affecting kidneys and liver; its expression spans liver, neurons, epithelia and leukocytes, its structure is stabilized by zinc binding and three disulfide bonds, and its dysregulation has been implicated in non-alcoholic steatohepatitis, rheumatoid arthritis, hepatocellular carcinoma and systemic amyloidosis, making it an emerging biomarker and therapeutic target across metabolic, inflammatory and neoplastic diseases.